How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper – Neumann – – British Journal of Clinical Pharmacology – Wiley Online Library The safety and efficacy of pharmacotherapy in children, particularly preterms, neonates and infants, is limited by a paucity of good-quality data from prospective clinical drug trials.…
Detailsc4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper by Aurich et al British Journal of Clinical Pharmacology – Wiley Online Library Children frequently respond differently to therapies compared to adults. Differences also exist between Paediatric age groups for pharmacokinetics and pharmacodynamics in both…
DetailsMeet the team behind c4c! We are a diverse group of people from many different backgrounds, but all of us are working towards a common goal: better medicines for children through European clinical trials. Today’s spotlight is on Lionel Tan, one of the industry representatives helping to steer the direction of c4c. Lionel Tan…
DetailsHow Can a Clinical Data Modelling Tool Be Used to Represent Data Items of Relevance to Paediatric Clinical Trials? Learning from the Conect4children (c4c) Consortium The c4c have published a new article on the Direcht clinical data modelling tool in Applied Sciences. “c4c is piloting the Direcht clinical data modelling tool to model their Cross Cutting…
Detailsc4c have published ‘Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project” in British Journal of Clinical Pharmacology. “The medicine development process is complex and requires time and effort to ensure safety, efficacy and quality. In paediatrics, this process is even more challenging, as it involves a subgroup of…
Details
